Cyxone's Drug candidate T20K demonstrates good safety margin

Cyxone has completed its first toxicity study of drug candidate T20K for the treatment of Multiple Sclerosis (MS) through the LPT Laboratory of Pharmacology and Toxicology GmbH in Germany.

The goal was to study whether T20k has toxic effects at dose levels that provide the desired effect against EAE ("animal-MS") in mice, i.e. 1 mg/kg. 

The study showed no adverse effects in mice dosed up to 75 mg/kg. The highest dose tested without any toxicity in this study was 25 mg/kg. Therefore, T20K has at least a 25-fold safety margin in treated mice i.p. (Toxic dose/effective dose).

Cyxone's CEO Kjell Stenberg remarks:

"Since drugs against MS generally have significant toxic effects in humans, which limit their practical use, it is very satisfying that T20K has such a large safety margin in animals. This indicates that T20K has the potential to be used in humans without major side effects."

2016-08-31

Contact
Cyxone AB (publ)
Kjell G. Stenberg, CEO
Tel: 070-716 80 09
E-mail: kjell.g.stenberg@cyxone.com
Adelgatan 21
221 22 Malmö
www.cyxone.com

This is information which Cyxone AB (publ) is required to publish under the EU Market Abuse Regulation. The information was provided by the auspices of the above contact person for publication on December 19, 2016 at. 09:25 CET.

About Cyxone
Cyxone AB (publ) is a biopharmaceutical company developing drugs based on cyclotides, a class of natural plant proteins. Cyclotide technology has the potential to provide new drugs offering beneficial pharmacological effects for diseases that currently lack effective and safe treatments. The company is focusing on the development of T20K, a substance which inhibits key processes in cells that are typically associated with various immune disorders, such as multiple sclerosis and rheumatoid arthritis. Cyxones Certified Adviser on Nasdaq First North is Consensus Asset Management AB.